Coreline Soft announced on the 15th that it has signed a memorandum of understanding (MOU) with Siemens Healthineers Korea for collaboration in medical AI technology. Through this agreement, Coreline Soft plans to combine its AI imaging analysis technology with Siemens Healthineers Korea’s advanced imaging equipment capabilities, focusing on improving AI diagnostic accuracy and automating medical workflows. The two companies will collaborate step by step on photon counting, expansion of the AI ecosystem based on CT (PCCT), co-planning AI algorithms using PET data, establishing a clinical validation and integration platform based in hospitals, and jointly entering the medical AI market. In particular, Siemens Healthineers holds world-class technology in the field of imaging diagnostics, leading the company to expect synergies through real-time integration of AI solutions and imaging equipment, as well as expanding supply via a device-software package model.
Daewoong Pharmaceutical announced on the 15th that it has revealed the latest research results related to the main ingredient deoxycholic acid (DCA) of its lipolytic injection ‘Violet’. Violet is the first domestic lipolytic injection launched in 2021. Safety and efficacy were verified through four large-scale clinical studies involving over 960 Koreans. According to the company, Violet is reliably supplied to over 2,000 hospitals and clinics nationwide, and after undergoing Phase 3 clinical trials and post-marketing surveys, it has been confirmed to be the only lipolytic injection whose efficacy and effectiveness are properly validated for Koreans. Daewoong Pharmaceutical is committed to promoting Violet’s differentiated strengths through continuous research and development as well as marketing activities, aiming to expand indications and actively target the market to grow Violet into a blockbuster product.
Seoul National University Hospital announced on the 15th that it will conduct a mega AI diffusion ecosystem project to improve the performance of artificial intelligence (AI) and develop services. This project is part of the ’2025 Mega AI Diffusion Ecosystem Creation Project', promoted by the Ministry of Science and ICT and the National Information Society Agency (NIA) of Korea. Among them, the consortium led by Seoul National University Hospital has been selected as the final implementing organization for the ‘Biomedical Signal Data Construction Project for Musculoskeletal Disorders’ in the beauty and health sector. The consortium, led by Professor Jo Min-woo of the Department of Convergence Medicine, includes PCN and All Big Data. The supportive budget is 580 million won. Additionally, the team led by Professor Jung Jae-woo from the Yonsei University Sports Science and Exercise Medicine Center, along with Gilon and Top Medical, will also be participating as partners.
PROTEINA held an IPO (initial public offering) briefing to introduce its listing plans and the company’s technological capabilities on the 15th. PROTEINA is a biotech company that analyzes protein-protein interactions (PPI), founded by Professor Yoon Tae-young of Seoul National University during his tenure at Korea Advanced Institute of Science and Technology (KAIST) in 2015. The company is set to go public on KOSDAQ on the 29th of this month. Its main technologies include ‘Landscape’, which finds and improves optimal antibodies by altering amino acid sequences, and ‘Fast Finder’, which analyzes protein interactions to discover biomarkers. Last April, PROTEINA received a national project grant in collaboration with researchers from Seoul National University, receiving 15 billion won over three years to study an ‘AI (artificial intelligence) antibody drug development platform.’
Ybrain announced on the 15th that it has exported its prescription electronic drug for depression, MindSteam, to Thailand for the first time. This export was conducted through Interpharma MedTech, a Thai medical device distribution specialized company. Interpharma MedTech is a subsidiary of Interpharma, one of Thailand’s top five pharmaceutical companies, serving major hospitals including Bumrungrad International Hospital and several university hospitals and military hospitals. The initial export volume is three MindSteams, and plans to continue supply will be based on local demand in Thailand. The Thai export approval utilized certification data recognizing the regulatory framework from the Food and Drug Administration (FDA) approval issued in 2021 and CE certification for MindSteam to navigate strict regulations. The company aims to investigate additional Southeast Asian countries where it can use FDA certification to expand its export reach.
JW Holdings announced on the 15th that it has joined the United Nations Global Compact (UNGC) to enhance the corporate sustainability management system to a global level. The UNGC (United Nations Global Compact) is the world’s largest corporate sustainability initiative established by the UN in 2000, encouraging companies to adhere to ten principles in four areas: human rights, labor, environment, and anti-corruption, while also participating in achieving the United Nations’ Sustainable Development Goals (SDGs). Currently, more than 25,000 companies and organizations from 167 countries around the world participate in the UNGC, and various companies in Korea are also joining to practice sustainable management.
Global medical aesthetics company Jeisys Medical announced on the 15th that it has participated in ‘ICLAS in JAPAN 2025’ held in Tokyo, Japan. This ICLAS, co-established by the Korean Society of Laser Skin and Hair and the Korean Society of Aesthetic Plastic Surgery, is an international conference attended by many medical professionals from Korea, Japan, and other major Asian countries. Jeisys Medical presented the latest treatment trends and clinical experiences using aesthetic medical devices. The company’s leading radio-frequency skin beauty devices ‘POTENZA’ and ‘DENSITY’ were displayed at their booth.